Physician profile
Keeli Stumbo
NPI 1790780468
$926.08
in general payments reported to CMS, 2019-2025
15 companies · $61.50 in 2025
The $61.50 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $55.45 · 2021: $373 · 2022: $94.21 · 2023: $163 · 2024: $179 · 2025: $61.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $403.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $153.15 | 2021-2022 | |
| Boston Scientific Corporation | $142.86 | 2021 | |
| Abbvie INC. | $121.51 | 2021 | |
| Lilly USA, LLC | $89.28 | 2024-2025 | Zepbound |
| Novo Nordisk INC | $77.50 | 2023-2025 | Wegovy, Saxenda |
| Acella Pharmaceuticals, LLC | $62.38 | 2024-2025 | NP Thyroid 60 |
| Bausch Health US, LLC | $61.98 | 2023 | Aplenzin |
| Exact Sciences Corporation | $57.25 | 2023-2024 | Cologuard Collection Kit |
| Medtronic USA, INC. | $39.78 | 2020 | |
| Mayne Pharma Commercial LLC | $35.33 | 2022-2023 | |
| Azurity Pharmaceuticals, INC. | $19.19 | 2023 | Adthyza |
| Astellas Pharma US INC | $18.57 | 2022 | |
| Currax Pharmaceuticals LLC | $16.68 | 2024 | Contrave |
| Collegium Pharmaceutical, INC. | $15.67 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $14.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keeli Stumbo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.